WuXi Biologics (Cayman) (HKG:2269) recorded a 1.3% decline in attributable profit for the year 2024 to 3.36 billion yuan from 3.4 billion yuan in the year-ago period, a Tuesday filing with the Hong Kong bourse said.
Earnings per share were 0.78 yuan in the year, up from 0.77 yuan in the previous corresponding year.
The vaccine maker's revenue rose by 9.6% to 18.7 billion yuan in the year from 17 billion yuan a year prior.
The higher revenue was mainly due to the successful execution of the company's "Follow and Win the Molecule" strategies, an enlarged spectrum of services offered to the biologics industry, growth of research services revenue, and the utilization of existing and newly expanded capacities.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。